EXACT Sciences (EXAS) Receiving Somewhat Positive News Coverage, Report Shows

News stories about EXACT Sciences (NASDAQ:EXAS) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. EXACT Sciences earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.5353829156777 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Shares of EXACT Sciences (EXAS) traded up $1.26 during trading hours on Monday, reaching $52.82. 1,287,941 shares of the company traded hands, compared to its average volume of 2,456,391. EXACT Sciences has a 12-month low of $13.05 and a 12-month high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. The company had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. EXACT Sciences’s quarterly revenue was up 158.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.36) earnings per share. equities analysts expect that EXACT Sciences will post -1.12 EPS for the current fiscal year.

Several research firms have recently issued reports on EXAS. Robert W. Baird lifted their price objective on shares of EXACT Sciences from $49.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 31st. Jefferies Group lifted their price target on shares of EXACT Sciences to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Benchmark reiterated a “buy” rating and set a $60.00 price target (up from $50.00) on shares of EXACT Sciences in a research note on Tuesday, October 31st. Canaccord Genuity reiterated a “buy” rating and set a $45.00 price target on shares of EXACT Sciences in a research note on Thursday, September 7th. Finally, Bank of America lifted their price target on shares of EXACT Sciences from $56.00 to $58.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Nine research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. EXACT Sciences currently has an average rating of “Hold” and an average price target of $50.58.

In other EXACT Sciences news, insider Kevin T. Conroy sold 134,057 shares of EXACT Sciences stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total value of $7,976,391.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP D Scott Coward sold 29,115 shares of EXACT Sciences stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the transaction, the senior vice president now owns 64,991 shares in the company, valued at $3,064,975.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 595,396 shares of company stock worth $32,953,769. 4.00% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/12/18/exact-sciences-exas-receiving-somewhat-positive-news-coverage-report-shows.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply